



26 May 2004

Dr. Gervasio A. Lamas MD  
Principal Investigator: Trial to Assess Chelation Therapy (TACT)  
Mount Sinai Medical Center  
4300 Alton Road, Suite 207A  
Miami Beach, FL 33140

Dear Dr Lamas:

On 14 Apr 2004, the DSMB overseeing your NIH-funded clinical trial met to review your progress. Particular attention was paid to subject recruitment and to adverse events. After review of these data, the DSMB unanimously recommended to the Director, NCCAM that the trial be allowed to continue unabated.

Sincerely,

Jonathan Berman MD PhD FAAP  
Executive Secretary, TACT DSMB  
Director, Office of Clinical and Regulatory Affairs  
National Center For Complementary and Alternative Medicine  
National Institutes of Health  
6707 Democracy Blvd, Suite 401  
Bethesda MD 20892 USA

Howard N. Hodis, M.D.  
Chair, TACT DSMB  
Professor of Medicine and Preventive Medicine  
Professor of Molecular Pharmacology and Toxicology  
Director, Atherosclerosis Research Unit  
Division of Cardiovascular Medicine  
University of Southern California School of Medicine  
2250 Alcazar St, CSC 132  
Los Angeles, CA 90033